Johnson & Johnson has entered into a deal to help develop a cancer compound discovered by Pharmacyclics in a deal that could be worth close to $1 billion to the latter.
J&J's Janssen Biotech subsidiary will jointly develop and market the drug, known as PCI-32765, which is in a number of Phase I and II studies "across a panel of B-cell malignancy disorders". These include chronic lymphocytic leukaemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.
PCI-32765 is an orally active, small molecule inhibitor of Bruton's tyrosine kinase, which J&J says is an essential element of the B-cell antigen receptor (BCR) signalling pathway. The latter is a critical pathway required for tumour expansion and proliferation.
Under the terms of the deal, Janssen has paid an upfront fee of $150 million, which will be recorded in the fourth quarter, and up to $825 million in development and regulatory milestone payments. The transaction, which will impact J&J's 2011 earnings per share by $0.04-$0.05, will see the firms share profits (and losses) 50/50, plus development costs (Pharmacyclics 40% and Janssen 60%).
William Hait, head of oncology at Janssen, said the agreement with Pharmacyclics "is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies". He added that PCI-32765 is "an innovative compound, with broad applicability and the potential to help a large number of patients".
Pharmacyclics chief executive Bob Duggan said that "over the past 18 months, we have met a number of outstanding individuals and very high quality organisations around the world. In the end, we felt that Janssen was the appropriate strategic fit for us and for PCI-32765".
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.